Table 1:

Patient demographics with MR imaging features and PCT measurements

No.	Age/Sex	Contrast Enhance-ment	Hemor-rhage	Necro-sis	Vasogenic Edema	Mass Effect	Signal Heterogeneity	Involvement of Corpus Callosum	Crossing Midline	MR Grade of Tumor	WHO Grade of Tumor	nCBV	nCBF	nMTT
1	20/M	HE	–	–	+	+	HT	+	+	HG	I	1.92	0.58	3.55
2	27/F	NCE	–	–	+	+	HO	–	–	LG	II	1.07	1.48	0.83
3	34/M	NCE	–	CD	+	++	HT	+	+	LG	II	0.94	1.26	1.07
4	56/F	HE	–	+	++	++	HT	–	–	HG	II	1.56	1.07	1.94
5	34/F	NCE	–	–	–	+	HO	–	–	LG	II	1.72	1.43	1.08
6	18/F	HE	–	+	–	+	HT	–	–	HG	III	2.26	1.53	1.41
7	39/M	HE	–	+	+	+	HT	–	–	HG	III	2.21	1.23	1.71
8	57/M	HE	+	+	+	+++	HT	–	–	HG	III	5.39	6.84	2.63
9	68/M	NCE	–	+	+	+	HT	–	–	LG	III	3.7	3.75	0.92
10	39/F	HE	+	+	++	+++	HT	+	+	HG	III	2.61	1.65	1.68
11	34/M	NCE	–	CD	–	++	HT	+	+	LG	III	1.5	0.78	1.32
12	64/M	PNE	+	+	++	+++	HT	+	+	HG	IV	1.96	1.19	1.78
13	39/F	PNE	–	+	++	+++	HT	+	–	HG	IV	2.05	1.07	1.51
14	55/F	PNE	–	+	++	+++	HT	+	+	HG	IV	3.95	2.87	1.11
15	60/M	PNE	+	+	+++	+++	HT	+	–	HG	IV	2.86	2.49	0.74
16	69/M	PNE	–	+	+	++	HT	–	–	HG	IV	1.12	1.69	1.04
17	66/F	HE	–	+	+	+	HT	+	–	HG	IV	5.3	6.16	0.77
18	46/M	HE	+	+	++	++	HT	+	+	HG	IV	4.3	6.27	0.63
19	57/M	PNE	–	+	+++	+++	HT	–	–	HG	IV	3.61	4.91	0.83

Note:—HE indicates heterogeneous enhancement; NCE, no contrast enhancement; PNE, peripheral nodular enhancement; CD, cystic degeneration; HT, heterogenous; HO, homogeneous; HG, high grade; LG, low grade; +, present; −, absent.